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ABSTRACT
This study evaluated the relationship between IL-2 cytokine secretion and CD4 T-lymphocyte depletion in People 
Living with HIV/AIDS (PLWHAS) in Enugu, Nigeria. Thirty (30) subjects were recruited into each of the three 
study groups:-Diagnostic HIV positive (A), HIV positive subjects on antiretroviral drugs (HAART) (B) and HIV 
negative control group (C). HIV load was estimated using Real-Time PCR with TaqMan Chemistry. Concentration 
of IL-2 cytokine was determined using ELISA technique, while CD4 T-lymphocyte count was done with C6 Acurri 
flow cytometer system. Levels of significance were tested using Mann-Whitney test, Kruskal-Wallis statistic and 
Dunn’s Multiple Comparison Test at p<0.05. IL-2 cytokine secretion increased significantly in group B
(99.32±43.83) as compared to A (52.57±23.53) and C (66.50±29.90). A significant reduction in mean CD4 T-
lymphocyte count in groups A (246.60±186.10) and B (255.40±168.70) was recorded. Similarly, the mean viral load 
of group B (145591.00±259499.00) was significantly reduced. Although there was elevation of IL-2 cytokine 
secretion during highly active antiretroviral therapy (HAART), with down regulation of viral burden, no 
corresponding increase in T-cell proliferation was recorded; indicating a possible qualitative defect in the IL-2 
cytokines produced during antiretroviral drug intervention or poor expression of IL-2 receptors on CD4 T-
lymphocytes. 
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INTRODUCTION 
Interleukin-2 (IL-2) is a T-cell-derived cytokine
known to be important in the regulation of growth 
and differentiation of T-cells, B-cells, natural killer 
cells, glioma cells and cells of the monocyte lineage 
after specifically interacting with its receptors. High-
affinity interleukin–2 receptor (IL-2R) is a 
heterotrimeric complex composed of the a-chain 
(CD25), β-chain (CD122), and the common y-chain 
(CD132) (Refachi et al., 1998).  Engagement of the 
IL-2R complex on activated T-cell initiates a 
complex signaling that can induce proliferation, 
increase survival as well as prime for activation-
induced cell death (Refachi et al., 1998). HIV infects 
primarily vital cells in the human immune system 
such as helper T-cells (especially CD4+ T-cells), 
macrophages, and dendritic cells (Cunningham et al., 
2010). HIV infection also leads to low level of CD4+
T-cells, through three main mechanisms which 
Include; direct viral killing of infected cells, 
increased rate of apoptosis in infected cells and 
killing of infected CD4+ T-cells by CD8 cytotoxic T-
lymphocytes.
Meanwhile, CD4 cells communicate with other 
cellular components of the immune system by either 
cell contact or the elaboration of soluble factors 
known as cytokines. There is a number of different 
cytokines, each having different and distinct actions. 
A bipolar Th1/Th2 concept was originally described 
in the mouse model, in which there was a division of 
CD4 cells into Th1 and Th2 cells based on the 
cytokine production from the respective cells (Gray 
et al., 2005). Th1 cells secrete cytokines that derive 
cell-mediated immunity. These cytokines are IL-1, 
IL-2, IL-6, IL-12, IL-15, tumor necrosis factor alpha 
(TNF-α), and interferon-γ. Th2 response derives a 
humoral immune response and stimulates B-cells. 
Th2 cytokines include IL-4, IL-5, and IL-10.
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On the other hand, the failure of the immune system 
to contain HIV is related to the functional impairment 
of HIV–specific CD4+ and CD8+ T-cells that 
accompanies progressive HIV infection, a 
phenomenon which is referred to as T-cell exhaustion 
(Day et al., 2006). It is known that the CD4+ T-cells 
(T–helper cells) play a major role in the overall 
immune responses by signaling other cells in the 
immune system to perform their respective functions 
(Deck et al., 2004; Ondoa et al., 2005). The 
mechanisms leading to T-cell exhaustion in HIV 
infection are clearly complex and cannot be attributed 
to a single pathway. In HIV–1 infection, the 
deterioration  of T cell responses involves the early 
loss of proliferative capacity, cytotoxic potential and 
the ability to produce interluikin–2 (IL-2), followed 
by a progressive loss of the ability to produce 
interferon gamma (INF-y) (Kostense et al., 2002).
Since nobody in our environment has looked at the 
effect of IL-2 cytokine level on CD4 T-lymphocyte 
proliferation and depletion during HIV infection, we 
designed this study to determine the relationship 
between CD4 T-lymphocyte depletion, IL-2 cytokine 
secretion and HIV viral load among people living 
with HIV and AIDS in Enugu, Nigeria.
MATERIALS AND METHODS
Subjects / Study Design: A total of ninety (90) 
subjects were recruited for this study. The subjects 
were divided into three groups with thirty (30) 
subjects in each study group. The groups included
thirty (30) HIV-1 positive subjects that have not 
started receiving antiretroviral drugs and referred to 
as Diagnostic HIV positive subjects (A); thirty (30) 
HIV-1 positive subjects on Highly Active 
Antiretroviral Therapy (HAART) (B); and thirty (30) 
apparently healthy individuals that have tested 
negative for antibodies to HIV-1 and 2, and used as 
control group (C). The test subjects were recruited 
from HIV/AIDS patients attending clinics at the 
University of Nigeria Teaching Hospital Ituku–
Ozalla; Enugu State University Teaching Hospital 
(Park Lane); Annunciation Specialist Hospital 
Emene; and Mother of Christ Specialist Hospital, all 
in Enugu, Nigeria. Control subjects were recruited 
from members of the public, students and staff of the 
hospitals stated above. Sample collection was 
completed within three months.
Inclusion / Exclusion criteria: This study included 
subjects based on the outcome of oral-
interview/questionnaire, clinical and laboratory 
assessments. Each person recruited after the 
assessment, was included as a participant after an 
informed consent was duly signed. The research 
considered only those on first line HAART drug 
combination and basically those on Zudovudine, 
lamivudine and nevirapine drug combination. With 
the approval of the ethics committee, the research 
was carried out at the Immunology Research Unit of 
the Department of Haematology and Immunology, 
University of Nigeria Teaching Hospital, Ituku–
Ozalla, Enugu State.
Ethical Approval: Ethical clearance approval was 
obtained from the Medical Research Ethics 
Committee of the University of Nigeria Teaching
Hospital, Ituku-Ozalla, Enugu. After critical study of 
the research proposal, a written approval was signed 
by the Committee. Each member of the recruited 
subjects read and signed the informed consent before 
enrollment as a participant. 
Blood Sample Collection: A total of 5mls of blood 
was collected from each subject into dipotassium 
ethylendiamine tetra-acetic acid (EDTA) bottle. The 
samples were maintained at 2 to 80C temperature 
range, and transferred immediately to the laboratory 
for analysis. Estimation of CD4 T-lymphocyte was 
carried out immediately while plasma sample was 
separated and kept in two aliquots for the estimation 
of IL-2 cytokine and viral load. The plasma samples 
were frozen at -850C.
Sample Analysis: HIV screening test was carried out 
with Genscreen ULTRA HIV Screening Kit for the 
detection of HIV P24 Antigen and Antibodies to 
HIV–1 and HIV–2 in Human Plasma by Enzyme 
Immunoassay (BIO–RAD). The GenscreenTM
ULTRA HIV Ag–Ab is an enzyme immunoassay 
based on the principle of the sandwich technique for 
the detection of HIV antigen and various antibodies 
associated with HIV–1 and / or HIV–2 virus in 
human serum or plasma. HIV–1/2 Confirmatory Test 
was done with Quali Code HIV–1/2 Kit, from 
Immunetics Inc. The Quali Code HIV–1/2 kit is a 
Qualitative Immunoblot Assay on the Western 
Blotting Principle. HIV RNA Extraction was carried 
out using Thermo Scientific Viral RNA Purification 
Kit from Thermo Fisher Scientific Inc while 
estimation of HIV Viral Load was done with Real 
Time-PCR method and TaqMan Chemistry. 
Estimation of IL-2 cytokine concentration was done 
with Abcam Human IL-2 ELISA Kit from Abcam 
UK. This is a solid phase sandwich enzyme linked-
immunosorbent assay kit. CD4 T-lymphocyte level 
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was estimated using Accuri cytometer (C6 flow 
cytometer system). A beam of light (usually laser 
light) of a single wavelength is directed onto a 
hydrodynamically focused stream of liquid to form 
both forward and side scatter. The combination of 
scattered and fluorescent light is picked up by a 
detector system to analyze and differentiate various 
types of structures of individual particle. 
Statistical Analysis: Levels of significance for IL-2 
cytokine and CD4 T-lymphocyte concentrations were 
tested with Kruskal-Wallis statistic and Dunn’s 
Multiple Comparison Test while Mann-Whitney test 
was used to test for viral load. The levels of 
significance were set at p < 0.05.
RESULTS
The mean value of IL-2 cytokine secreted in the 
plasma of diagnostic HIV positive subjects (52.57 ± 
23.53) differs significantly from that of HIV positive 
subjects on antiretroviral (ARV) drugs (99.32 ± 
43.83) when compared statistically (p<0.05). There is 
also statistically significant difference between the 
mean values of IL-2 plasma levels of HIV positive 
subjects on ARV drugs (99.32 ± 43.83) and HIV 
seronegative control subjects (66.50 ± 29.90) 
(p<0.05).  There was no significant difference 
observed when the mean values of IL-2 plasma level 
of diagnostic HIV positive subjects (52.57 ± 23.53) 
was statistically compared with that of the control 
subjects (66.50 ± 29.90). 
In Table 2 the mean value of CD4+ T-lymphocyte 
count in diagnostic HIV positive subjects 
(246.60±186.10) was significantly reduced (P<0.05) 
in comparison with that of the HIV seronegative 
control subjects (996.40 ± 207.10). Also, the mean 
CD4+ T-lymphocyte count of HIV positive subjects 
on antiretroviral drugs (255.40±168.70) showed 
statistically significant, (P<0.05) when compared 
with that of the control group (996.40±207.10). At 
5% level of significance, there was no statistically 
significant difference observed when the mean CD4+
T-lymphocyte count of diagnostic HIV positive 
subjects (246.60±186.10) was compared with that of 
the HIV positive subjects on antiretroviral drugs 
(255.40±168.70), (p>0.05).
The mean viral load of HIV positive subjects on 
ARV drugs (145591.00±259499.00) was 
significantly reduced when statistically compared 
with that of diagnostic HIV positive subjects 
(24407.00±106479.00) (p<0.05)
Table 1: Plasma IL–2 levels in diagnostic HIV positive subjects, HIV positive subjects on ARV drugs 
(HAART) and HIV Seronegative control subjects.
Parameters (pg/ml) Diagnostic HIV ARV Drugs HIV Seronegative
Median 47.26 107.7 65.82
Mean 52.57 99.32 66.50
Standard Deviation 23.53 43.83 29.90
Minimum (pg/ml) 34.26 17.06 17.79
Maximum (pg/ml) 143.10 180.80 130.20
Normality No Yes Yes
For Dunn's Multiple Comparison Test -Diagnostic (52.57±23.53) vs ARV (99.32±43.83): Diff in rank sum = -30.98 
(P<0.05); Diagnostic (52.57±23.53) vs Control (66.50±29.90): Diff in rank sum =-13.37 (P>0.05); ARV
(99.32±43.83) vs Control (66.50±29.90): Diff in rank sum = 17.62 (P<0.05).
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Table 2: CD4+ T-lymphocyte levels in diagnostic HIV positive subjects, HIV positive subjects on ARV drugs 
and HIV Seronegative control subjects.
Parameters (cells/µl) Diagnostic HIV ARV Drugs HIV 
Seronegative
Median 177.00 202.50 976.50
Mean 246.60 255.40 996.40
Standard Deviation 186.10 168.70 207.10
Minimum 85.00 97.00 681.00
Maximum 920.00 819.00 1366.00
Normality Yes Yes Yes
For Dunn's Multiple Comparison Test -Diagnostic (246.60±186.10) vs ARV (255.40±168.70): Diff. in rank sum
=3.367 (P>0.05); Diagnostic (246.60±186.10) vs Control (996.40±207.10): Diff. in rank sum = -45.58 (P<0.05);   
ARV (255.40±168.70) vs Control (996.40±207.10): Diff. in rank sum = -42.22 (P<0.05)
Table 3: Quantitative HIV virus in Diagnostic HIV Positive Subjects and HIV positive subjects on 
Antiretroviral Drugs (HAART).
Parameters (copies/ml) Diagnostic HIV ARV Drugs 
Median 20646.00 0.00*
Mean 145591.00 24407.00




*Medians were significantly different
DISCUSSION
In this study, low level of plasma IL-2 cytokine 
observed in Diagnostic HIV-positive subjects in spite 
of high viral load and constant immune challenges by 
the viral particles may be attributed to the observed 
low CD4+ T-lymphocyte count in the same group. It 
is known that CD4+ T-cells secrete IL-2 cytokines 
which in turn activates the proliferation of both CD4+
and CD8+ T-lymphocytes (Refachi et al., 1998). Low 
level of CD4+ T-lymphocyte may possibly lead to 
low synthesis of IL-2 cytokine and low activation of 
both CD4+ and CD8+ T-lymphocytes. This may 
further reduce the capacity of the immune system to 
modulate the proliferative rate and expansion of HIV 
virus in the system. The significant increase in 
plasma IL-2 level of HIV-positive subjects on ARV 
drugs observed in this study in comparison with both 
diagnostic HIV-positive and HIV-seronegative 
control groups may then be attributed to the impact of 
highly active antiretroviral drugs (HAART) on the 
viral particles. 
However, CD4 molecules found on the surface of 
helper T-lymphocytes, and other CD4+ - cells like 
monocytes, macrophages and dendritic cells help to 
stabilize the binding of T-lymphocytes to the major 
histocompatibility complex (MHC) class II on the 
antigen presenting cells (APC).  Activation of T-
helper cells through such binding orchestrates the 
body’s antigen-specific immune response by 
coordinating B-lymphocyte production of antibodies, 
secretion of cytokines by various immune cells and 
induction of cytotoxic lymphocyte response to the 
antigens.  These functions make CD4+ T-
lymphocytes critical elements of the immune system 
(Wilson et al., 2004; Vajpayer et al., 2005; Vajpayer 
et al., 2009). Low level of CD4 T-lymphocytes found 
in Diagnostic HIV positive subjects may account for 
the increase in viral load observed in this group. 
In addition, HIV has direct and indirect cytolytic 
effect on both mature CD4+ T-cells and on the 
progenitor cells which is the reason for progressive 
exhaustion that accompanies the loss of capacity to 
produce new cells (Antran, 2000; Brenchley et al., 
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2004; Choadhry et al., 2007; Appay and Sauce, 
2008). Therefore, the observed high level of viral 
load in Diagnostic HIV positive subjects may as well 
be attributed to low level of CD4 T-lymphocyte 
count. Clearance or reduction in plasma viral load 
during antiretroviral therapy can reduce the cytolytic 
effect of the virus on CD4+ T-lymphocytes and lead 
to increase in absolute CD4+ T-cell count. Increase in 
CD4+ T-cells count may lead to increase in IL-2 
syntheses which may up-regulate the activation and 
proliferation of CD4+ and CD8+ T-lymphocytes.  
CD8+ T-cell activation may increase the immune 
activity against the virus, augmenting the action of 
HAART therapy and restoring the physiological 
condition of the patient.
Contrary to this expectation, there was no significant 
increase in CD4 T-lymphocyte count in HIV positive 
subjects on antiretroviral drugs when compared with 
that of the Diagnostic HIV positive subjects even 
with a very significant increase in IL-2 cytokine 
secretion. It may imply that reduction or clearance of 
HIV virus in the blood may induce secretion of IL-2 
cytokine even with little increase in CD4 T-
lymphocyte count. The IL-2 cytokine produced under 
this condition may not have proliferative capacity to 
affect a corresponding increase in CD4 T-lymphocyte 
count. This observation may be a proliferative 
dysfunction induced on the CD4 T-lymphocyte 
progenitor cells by HIV particles during progressive 
HIV infection.
CONCUSION
HIV infection causes decrease in IL-2 cytokine 
secretion. Clearance of HIV particles or reduction in 
viral load by antiretroviral intervention leads to 
increase in both CD4 T-lymphocyte count and IL-2 
cytokine secretion. But increase in IL-2 cytokine 
secretion during antiretroviral therapy does not lead 
to a corresponding increase in CD4 T-lymphocyte 
count. This may indicate a qualitative impairment of 
the IL-2 cytokines produced during antiretroviral 
therapy or poor expression of IL-2 cytokine receptor 
(IL-2R) complex, on activated T-helper cells. 
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